Lyra therapeutics reports positive results from the enlighten 2 phase 3 trial of lyr-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of chronic rhinosinusitis (crs)

Watertown, mass., june 02, 2025 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (crs), today announced positive results from the enlighten 2 phase 3 clinical trial of lyr-210 in adult patients with crs. the enlighten 2 trial met its primary endpoint, with lyr-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3cs) of crs (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.
CRS Ratings Summary
CRS Quant Ranking